What it is
Tesamorelin is a synthetic growth-hormone-releasing-hormone analogue. It holds regulatory approval in some jurisdictions for a specific prescription indication; approval does not extend to general wellness or body-composition use.
The Range
IPA · Pen · Endocrine research
Tesamorelin 5 mg pen
Approved medicineEvidence: Established
A GHRH analogue approved in certain markets for a specific, narrowly defined clinical indication under prescription and specialist oversight.
Information only
Tesamorelin is presented as reference information for registered healthcare professionals. Availability is subject to applicable law, prescription or Section 21 authorisation, and licensed pharmacy channels. No dosing, protocol or self-administration guidance is given, and nothing here is an offer of sale.
Evidence highlights
Mechanism being studied
Stimulates endogenous growth-hormone release via GHRH receptor agonism.
Human evidence
Randomised controlled trials support its approved indication in the populations studied. Evidence outside that approved indication is limited and does not support general use.
Evidence & Regulation
Where the evidence for Tesamorelin sits, and the rules that apply to it
Every source below is a public, primary source — a literature index, a trials registry, or a regulator. They are reading directions for professionals, not endorsements, and they do not establish that any use of Tesamorelin is approved, safe or appropriate.
Citations
- Peer-reviewed literature — PubMed search: "tesamorelin"
LiteratureIndependent index of published studies. Most entries for research peptides are preclinical.
- Registered clinical trials — ClinicalTrials.gov: "tesamorelin"
Clinical trialsShows whether the compound is being studied in authorised human trials, and at what phase.
- European Medicines Agency — medicines database
RegulatorCheck whether a marketing authorisation exists in the EU and read the assessment report if it does.
- WADA Prohibited List
SportNon-approved substances (class S0) and growth-factor classes are prohibited in sport at all times.
Further reading
- Regulator-approved product information in markets where registered.
- Randomised controlled trials supporting the approved indication.
How the regulation works
Registration comes before supply
In South Africa, a product intended to treat, prevent or otherwise affect the functioning of the body is a medicine and must be registered with SAHPRA before it may lawfully be sold. An unregistered compound cannot be advertised or supplied to the public, regardless of the evidence behind it.
SAHPRA — medicines registrationSection 21 is the professional access route
Where no registered alternative exists, a registered healthcare professional may apply to SAHPRA under Section 21 for authorisation to access an unregistered product for a named patient. That application is made by the clinician, not by the patient, and not by us.
Section 21 pathwayPrescription and dispensing stay with licensed channels
Any prescribing decision, dosing decision and dispensing step belongs to a registered healthcare professional and a licensed pharmacy. We publish reference information and analytical documentation only, and never dosing, protocols or self-administration guidance.
Prohibited in sport
Non-approved substances are prohibited at all times under the World Anti-Doping Code, including many research peptides. Athletes under testing jurisdiction should treat every compound on this site as prohibited unless their governing body confirms otherwise.
WADA Prohibited ListStatus is jurisdiction-specific
A compound may be an approved medicine in one country, an investigational agent in a second, and an unregistered research chemical in a third. Always confirm the classification that applies where you practise before acting on any information here.
EMA medicines databaseInformation only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.